Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Daily adaptive SBRT with urethral sparing: The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
Study summary
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Eligibility
Primary outcome measure(s)
- Patient-reported acute urinary toxicity — 90 days after end of SBRT
Minimum clinically important change (MCIC) status in patient-reported urinary QOL, as determined by the worst change reported by each subject in their EPIC-26 urinary domain scores.
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| Duarte Cancer Center | Duarte | California | Recruiting |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | California | Recruiting |
| Brigham and Women's Hospital | Boston | Massachusetts | Active Not Recruiting |
| Washington University in St. Louis | St Louis | Missouri | Recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | Active Not Recruiting |
| Klinikum der Landeshauptstadt Stuttgart gKAöR | Stuttgart | Baden-Wurttemberg | Recruiting |
| Universitätsklinikum des Saarlandes (Saarland Univerisity Hospital) | Homburg | Saarland | Recruiting |
| Hospital Universitario de Navarra | Pamplona | Navarre | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05804318 on ClinicalTrials.gov ↗ ← All trials in Spain